Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04790552 · ClinicalTrials.gov registry record · NA

Effects of Fast Bar on Intermittent Fasting

A NA study, sponsored by L-Nutra.

Completed
Registry status
NA
Development phase
89
Enrollment target

NCT04790552: Completed NA study, sponsored by L-Nutra.

NCT04790552 is a NA study that has completed, run by L-Nutra. The registered enrollment target is 89 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04790552, a NA study, has completed, sponsored by L-Nutra.

COMPLETED
Registry status
NA
Development phase
89 participants
Enrollment target

Study Summary

This study evaluates how Fast Bar(TM), a specially formulated energy bar, when consumed with coffee or tea, affects the physiological condition in participants after an overnight fasting. Participants will fast for 19 hours (Fast Group), consume a Fast Bar in the night (Night Bar Group) or in the morning (Bar+Coffee and Bar+Tea Groups) after an approximately 15-hour overnight fasting. Participants will be assessed for physiological parameters associated with fasting.

Primary Outcome

Blood ketone (ß-hydroxybutyrate, BHB) level (mg/dL) will be measured with a Abbott Precision Xtra Blood Glucose and Ketone Monitoring Kit.

Interventions

  • OTHER Fasting
  • OTHER Dinner
  • OTHER Fast Bar
  • OTHER Bar with Coffee
  • OTHER Bar with Tea

Trial Details

FieldValue
Enrollment Target 89 participants
Start Date 2021-03-01
Est. Completion 2021-08-14
Phase NA
L-Nutra

5 total trials

What the finished NCT04790552 record still lists

NCT04790552 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 5 interventions - of which Fasting is the first listed.

NCT04790552 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04790552 about?

NCT04790552 is a clinical study titled "Effects of Fast Bar on Intermittent Fasting". This study evaluates how Fast Bar(TM), a specially formulated energy bar, when consumed with coffee or tea, affects the physiological condition in participants after an overnight fasting. Participants will fast for 19 hours (Fast Group), consume a Fast Bar in the night (Night Bar Group) or in the mo...

What is the current status of trial NCT04790552?

This trial is currently completed. It is a NA study. The enrollment target is 89 participants. The study started on 2021-03-01. Estimated completion is 2021-08-14.

What interventions are being tested in trial NCT04790552?

The interventions under investigation include: Fasting (OTHER), Dinner (OTHER), Fast Bar (OTHER), Bar with Coffee (OTHER), Bar with Tea (OTHER).

Who is sponsoring clinical trial NCT04790552?

This trial is sponsored by L-Nutra, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04790552's enrollment target sits among peer trials

89 972nd of 2000 higher than 1,029 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03682289 · 89 participants · Phase 2

    Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

  • NCT04787939 · 89 participants · NA

    Early Feeding After Oral Cavity Reconstruction

  • NCT05480449 · 89 participants · Phase 1

    Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

  • NCT05604131 · 89 participants · Phase 2

    Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04790552, the US trial registry maintained by the National Library of Medicine. NCT04790552 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.